A phase 1 clinical trial (NCT02924402) evaluating its safety and tolerability in patients with CD20-expressing hematologic malignancies is ongoing and demonstrated so far evidence of clinical activity in heavily pretreated patients with DLBCL and FL, including earlier treatment with CAR-T therapy (129, 130). This evidence concerns the gene MS4A1 and hematologic disorder.